Vancomycin Enema denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for vancomycin enema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Vancomycin Enema as Not FDA-Approved

Vancomycin enema is a compounded formulation — the FDA has not approved an enema dosage form of vancomycin as a finished drug product. Humana routinely denies compounded preparations under a "not FDA-approved" exclusion because their formulary and coverage policies are anchored to commercially manufactured, FDA-reviewed products. However, this denial type is among the most commonly overturned on appeal: compounded vancomycin enema is prescribed by gastroenterologists for specific colorectal conditions when commercially available formulations cannot reach the affected tissue, and that clinical rationale is precisely the kind of medical-necessity argument that survives external review.

## Why This Denial Is Appealable

Federal law does not require every covered drug to hold an FDA approval for the specific route of administration used, provided the prescriber documents that the compounded form is medically necessary and that no approved alternative is clinically equivalent. The ACA and state pharmacy compounding laws protect access to legitimate compounded preparations when a licensed prescriber documents individualized need. Humana's own coverage policy typically carves out an exception for compounded drugs when medical necessity is established — obtain and read that policy section carefully before drafting your appeal.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe shown on the denial notice (typically 180 days for ACA plans, 60 days for ERISA group plans). Humana must respond within 30 days for pre-service and 60 days for post-service internal appeals.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you are entitled to an independent external review by an accredited Independent Review Organization (IRO). Request this within approximately 4 months of the final internal denial. The IRO's decision is binding on Humana.
• Expedited option: If waiting poses serious risk to health, request expedited review simultaneously with the internal appeal; Humana must respond within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing the specific colorectal condition requiring localized vancomycin delivery.
• Prior-treatment history: Dates and outcomes of all commercially available oral and IV alternatives tried, including any intolerances or treatment failures.
• Clinical rationale for route: Prescriber explanation of why an oral or intravenous formulation cannot achieve adequate drug concentration at the treatment site.
• Prescriber medical-necessity letter: A detailed letter from the treating gastroenterologist or colorectal surgeon stating why the compounded enema formulation is the only clinically appropriate option for this patient.
• Compounding pharmacy documentation: Confirmation that the preparation will be made by a licensed, compliant compounding pharmacy.

## Criteria-Mapping Structure

Pull Humana's published medical policy for compounded drugs and list every stated coverage requirement. For each requirement, cite the exact chart entry, lab value, or clinical note that satisfies it. Present this as a side-by-side table in your appeal letter so the reviewer can confirm compliance without interpretation.